INVO Fertility Amends 10-K, Discloses $1M+ Related Party Debt and Executive Compensation Amid Going Concern Warning
IVF is trading near its 52-week low of $1.265 (13% above the low) on light trading volume (0.2× avg).
Summary
INVO Fertility filed an amended 10-K, detailing over $1 million in related party debt and significant executive compensation, adding crucial context to its previously disclosed 'going concern' warning and financial restatements.
Key Events · Corporate Governance and Compliance · IVF
-
Amends Prior 10-K Filing
This 10-K/A provides the previously omitted Part III information (Directors, Executive Officers, Corporate Governance) for the fiscal year ended December 31, 2025, following the original 10-K filing on June 2, 2026, which included a 'going concern' warning and restatements.
-
Significant Related Party Debt Disclosed
The company disclosed $660,000 in principal plus $120,437 in accrued interest on notes payable to JAG (an entity where the CBO is a beneficiary), and $220,000 in principal plus $62,460 in accrued interest on notes payable to the CEO and an entity controlled by the CBO. Total related party obligations exceed $1 million, representing over 40% of the company's market capitalization.
-
Substantial Executive Compensation
For 2025, CEO Steven Shum received $430,863, CFO Terah Krigsvold received $336,474, and CBO Andrea Goren received $282,530. The combined compensation for these three executives totals over $1 million, which is approximately 40% of the company's current market capitalization.
-
Clawback Policy Review After Restatement
Following the restatement of Q1-Q3 2025 financials due to multiple accounting errors, the Compensation Committee determined that no incentive compensation was subject to recovery under the Clawback Policy, as the errors did not impact revenue or loss from operations.
Analysis · IVF · Industrial Applications And Services
This amended 10-K provides critical Part III information that was missing from the original filing, which previously disclosed a 'going concern' warning, financial restatements, and material weaknesses. The amendment reveals over $1 million in related party debt owed to entities connected to the CEO and Chief Business Officer, representing a substantial portion of the company's market capitalization. Additionally, the executive compensation for 2025 totals over $1 million for the top three officers, which is also a significant amount for a company facing severe financial distress. The disclosure that no incentive compensation was clawed back despite the restatement, due to the accounting errors not impacting revenue or loss from operations, is also notable given the company's precarious state.
At the time of this filing, IVF was trading at $1.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $1.27 to $183.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.